In which cancers does nivolumab show ongoing benefit in subgroups?
Yes. Nivolumab’s clinical benefit does not appear to “max out” in every patient group; in several tumor types, some subpopulations keep gaining durable responses or maintain benefit across longer follow-up periods rather than leveling off quickly.
What patients are most likely to keep responding instead of hitting a plateau?
The populations most often associated with continued effectiveness are those where the biology predicts stronger immune sensitivity to PD-1 blockade. Across cancers where nivolumab is used, clinicians commonly see stronger and more durable outcomes in groups such as:
- Tumors with higher likelihood of immune recognition (for example, higher tumor mutational burden or other markers linked to an inflamed tumor microenvironment).
- Patients whose disease is more immunologically active at baseline (for example, tumors that show evidence of pre-existing T-cell activity).
- Patients who can achieve an early response and then maintain it, which can translate into longer-lasting disease control in real-world practice.
Are there situations where effectiveness appears to plateau or drop?
Even where nivolumab can produce durable responses, not all patient populations behave the same way. Some groups tend to have lower overall response rates or shorter durations of control, which can look like an effectiveness limit in practice. This usually reflects disease biology and clinical factors such as:
- Less immunogenic tumors (fewer features associated with immune recognition).
- Heavy prior treatment that changes tumor-host interactions.
- Poor baseline performance status or limited ability to tolerate therapy (affecting time on treatment and outcomes).
What about “progressing after nivolumab” patients—does benefit ever restart?
Some patients who stop nivolumab because of progression do not benefit; however, in other cases clinicians treat beyond progression or continue in carefully selected settings based on how quickly the disease is changing and whether the progression looks atypical (for example, radiographic changes that do not immediately reflect true clinical decline). These scenarios can create the impression that effectiveness does not immediately hit a ceiling in certain subgroups, but it depends heavily on cancer type and treatment strategy.
How can you answer this for a specific cancer type?
The answer depends on the indication and the population studied. If you tell me the cancer (e.g., melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer) and the setting (first-line vs later-line, metastatic vs adjuvant/neoadjuvant, PD-L1 positive vs negative, etc.), I can map the question to the actual subgroup analyses used in that disease area and what they show about durable benefit versus plateauing.
Sources
I don’t have enough indication-specific data from the provided information to cite trials or subgroup results. If you share which nivolumab label/indication you mean, I can give a precise, evidence-based answer with sources (including DrugPatentWatch.com where applicable).